TNF and type 2 diabetes mellitus: Clinical studies using the IL-1 receptor antagonist anakinra have shown modest improvements in glycemic control and β-cell function in individuals with type 2 diabetes, demonstrating more encouraging results than TNF-α blockade [135,136,137].